Jazz Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.05.17	Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status (PR Newswire)
31.05.17	Research Reports Initiation on Biotech Stocks -- Kite Pharma, Arrowhead Pharma, Ultragenyx Pharma, and Jazz Pharma (PR Newswire)
24.05.17	Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS (PR Newswire)
24.05.17	Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS (PR Newswire)
24.05.17	Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP... (PR Newswire)
24.05.17	Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP... (PR Newswire)
16.05.17	Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences (PR Newswire)
09.05.17	Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results (PR Newswire)
09.05.17	Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results (PR Newswire)
26.04.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness (PR Newswire)
25.04.17	Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 (PR Newswire)
25.04.17	Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 (PR Newswire)
25.04.17	D-Day For CAPR Today, OMED Hands Out Pink Slips, JAZZ Hits Right Notes... (RTTNews)
24.04.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy (PR Newswire)
24.04.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy (PR Newswire)
06.04.17	ARLZ Hands Out Pink Slips, JAZZ On A High Note, STDY On Track, TENX Abuzz (RTTNews)
05.04.17	Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation (PR Newswire)
05.04.17	Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation (PR Newswire)
03.04.17	Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia (PR Newswire)
03.04.17	Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia (PR Newswire)
30.03.17	Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan (PR Newswire)
30.03.17	Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan (PR Newswire)
21.03.17	PTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right Notes (RTTNews)
20.03.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea (PR Newswire)
20.03.17	Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea (PR Newswire)
15.03.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy (PR Newswire)
15.03.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy (PR Newswire)
01.03.17	Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March (PR Newswire)
01.03.17	Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March (PR Newswire)
28.02.17	Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results (PR Newswire)
28.02.17	Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results (PR Newswire)
14.02.17	Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017 (PR Newswire)
14.02.17	Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017 (PR Newswire)
09.02.17	AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban (RTTNews)
08.02.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease (PR Newswire)
08.02.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease (PR Newswire)
30.01.17	Research Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx Pharma (PR Newswire)
19.01.17	Gainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC... (RTTNews)
18.01.17	ADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study (RTTNews)
17.01.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients (PR Newswire)
17.01.17	Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients (PR Newswire)
07.12.16	Technical Reports on Biotech Equities -- Jazz Pharma, Anthera Pharma, ProNAi Therapeutics, and AveXis (PR Newswire)
29.11.16	FOLD Shrinks, JAZZ On Right Track, NVLS Choked Up, AAAP On Watch, NVRO Sues BSX (RTTNews)
28.11.16	Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy (PR Newswire)
28.11.16	Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy (PR Newswire)
04.10.16	DVAX Back In News, Spectral Shock For Investors, MACK Giving Pink Slips (RTTNews)
27.09.16	ARRY Hits COLUMBUS Goals, KITE Flies After-hrs, FDA Places Hold On CVM Trial (RTTNews)
31.05.16	MÄRKTE USA/Wall Street beendet den Mai uneinheitlich (Dow Jones)
31.05.16	MÄRKTE USA/Verhalten freundliche Stimmung setzt sich fort (Dow Jones)
31.05.16	MÄRKTE USA/Freundliche Stimmung dürfte sich fortsetzen (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Jazz Pharmaceuticals PLC

Aktien Top/Flop

Meistgelesene Nachrichten